A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia
Response to Goldberg et al.
- David S.H. Bell, MB, FACE
- From the Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
- Address correspondence to David S. H. Bell, MB, FACE, Faculty Office Tower, Room 754, 510 South 20th St., Birmingham, AL 35294.
E-mail: dshbell{at}uab.edu
The study by Goldberg et al. (1) in the July issue of Diabetes Care concluded that, compared with rosiglitazone, pioglitazone was associated with improvements in triglycerides, HDL cholesterol,
LDL concentration, and LDL particle size.
It should first be noted that 4,410 subjects were screened to obtain 735 eligible subjects. This was a highly selective group,
and therefore this was an enriched study. Second, recognized goals for the diabetic patient were not reached with either pioglitazone
or rosiglitazone for triglycerides, non-HDL cholesterol, and LDL cholesterol. Third, HDL particle size, which should have
been available from the proton nuclear magnetic resonance spectroscopy of Liposcience, was not reported. Why was this omitted
from both the American Heart Association presentation and the Diabetes Care study?
Finally, and most importantly, based on the Collaborative Atorvastatin Diabetes and Heart Protection Studies (2,3), it is now well recognized that irrespective of LDL levels, all type 2 diabetic patients benefit from statin therapy. Without
concomitant statin therapy, these results have little clinical significance. This is especially important since two studies
have clearly shown that when simvastatin or ezetimibe are coadministered with thiazolidinediones there are no significant
differences in the lipid profile of those subjects on pioglitazone or rosiglitazone (4,5).
It is now clear for many studies that rosiglitazone does not decrease fasting triglycerides. However, two recent studies have
shown that rosiglitazone does significantly decrease postprandial triglyceride levels. One study has shown that this is not
the case with pioglitazone (8). While uncertainty surrounds the role of fasting triglycerides as a cardiac risk factor, there is little doubt that elevated
postprandial triglycerides are a risk factor (9).
References
- ↵
Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA, Tan MH, Khan MA, Perez AT, Jacober SJ, the GLAI Study Investigators:
A comparison of lipid and glycemic effects of pioglitazone in patients with type 2 diabetes and dyslipidemia.
Diabetes Care
28
:
1547
–1554,2005
- ↵
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V,
Fuller JH, the CARDS Investigators: Primary prevention of cardio vascular disease with atorvastatin in type 2 diabetes in
the Collaborative Atorvastatin Diabetes Study (CARDS) multicenter randomized placebo controlled trial.
Lancet
364
:
685
–696,2004
- ↵
Collins R, Armitage J, Parish S, Sleigh P, Peto R, the Heart Protection Study Collaborative Group: MRC/BHF Heart Protection
Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial.
Lancet
361
:
2005
–2016,2003
- ↵
Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA, the Simvastatin/Thiazolidinedione
Study Group: Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when
added to a thiazolidinedione therapy in patients with type 2 diabetes mellitus: a multicenter, randomized double blind placebo
controlled trial.
Clin Ther
36
:
379
–389,2004
- ↵
Gaudiani LM, Lewin A, Meneghini L, Perevozskaya I, Plotkin D, Mitchel Y, Shah S: Efficacy and safety of ezetimibe co-administered
with simvastatin in thiazolidinedione treated type 2 diabetic patients.
Diabetes Obes Metab
7
:
88
–97,2005
-
Tan GD, Fielding BA, Currie JM, Humphreys SM, Desage M, Frayn KN, Laville M, Vidal H, Karpe F: The effects of rosiglitazone
on fatty acid and triglyceride metabolism in type 2 diabetes.
Diabetologia
48
:
83
–95,2005
-
Van Wijk JPH, de Koning EJP, Castro Cabezas M, Rabelink TJ: Rosiglitazone improves postprandial triglyceride and free fatty
acid metabolism in type 2 diabetes.
Diabetes Care
28
:
844
–849,2005
- ↵
Shimono D, Kuwamura N, Nakamura Y, Koshiyama H: Lack of effect of pioglitazone on postprandial triglyceride levels in type
2 diabetes.
Diabetes Care
24
:
971
,2001
- ↵
Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, Hennekens CH: A prospective study of triglyceride level, low-density
lipoprotein particle diameter and risk of myocardial infarction.
JAMA
276
:
882
–888,1996
